Log In
Print this Print this

GBO-006, ON 1231320

  Manage Alerts
Collapse Summary General Information
Company Onconova Therapeutics Inc.
DescriptionLipid-based nanosuspension formulation of a polo-like kinase 2 (PLK2) inhibitor
Molecular Target Polo-like kinase 2 (PLK2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat triple-negative breast cancer (TNBC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today